$XTALPI(02228.HK) Just learned about the introduction of Signet's orphan drug nominated for a major prize by Jingtai Investments, as follows: (Voice-to-text is being edited, apologies everyone)

It has obtained accelerated qualification, so it can enter the fast track, and there is still hope that it will be exempted from Phase III clinical trials. In the U.S., it is marketed as a rare disease model for gastric cancer and then expanded to other regions. First, in the Asia-Pacific region, the base patient population for gastric cancer is already large. Later, it may also target the elimination of ascites. Signet's effect is also very good, as many patients with visceral cancers also have concurrent ascites issues. This single drug eliminates 90% of ascites symptoms. The potential of this drug is enormous.